With the explosion of advanced digital innovations now employed across all aspects of drug development, the journey of a data point is no longer linear. But what does its new journey look like? What is the feedback loop from patients and clinicians to early development scientists and vice versa? How has this changed collaboration within companies and with their external partners? Are these long-sought efficiencies creating new challenges? How can companies ensure strategic and thoughtful investments in these data-first approaches? And most importantly, what do any of these ultimately do for patients?